Cargando…

Absence of specific cutaneous manifestations of severe acute respiratory syndrome coronavirus 2 in a reference center in Brazil

Detalles Bibliográficos
Autores principales:	Avancini, Joao, Miyamoto, Denise, Arnone, Marcelo, Gabbi, Tatiana Villas Boas, Ferreira, Paula Silva, Festa-Neto, Cyro, Sanches, Jose Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the American Academy of Dermatology, Inc. 2021
Materias:	JAAD Online
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491481/ https://www.ncbi.nlm.nih.gov/pubmed/32946969 http://dx.doi.org/10.1016/j.jaad.2020.09.030

Ejemplares similares

Cutaneous manifestations in COVID-19: Lessons learned from current evidence
por: Suchonwanit, Poonkiat, et al.
Publicado: (2020)

Dermatologic manifestations of hydroxychloroquine therapy: A closer look at the nails
por: Lipner, Shari R., et al.
Publicado: (2020)

Reply to: “A dermatologic manifestation of COVID-19: Transient livedo reticularis”
por: Thomas, Cristina
Publicado: (2020)

Reply to: “Reply: A dermatologic manifestation of COVID-19: Transient livedo reticularis”
por: Manalo, Iviensan F., et al.
Publicado: (2020)

The oral cavity cannot be forgotten in the COVID-19 era: Is there a connection between dermatologic and oral manifestations?
por: Bemquerer, Larissa Marques, et al.
Publicado: (2021)

Comment on “The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries”
por: Baab, Kelsey, et al.
Publicado: (2021)

Response to: “Comment on ‘The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries’”
por: Freeman, Esther E., et al.
Publicado: (2021)

Reply to “Varicella-like exanthem as a specific COVID-19–associated skin manifestation: multicenter case series of 22 patients”: Discussing specificity
por: Ortega-Quijano, Daniel, et al.
Publicado: (2020)

Response to McMahon et al's “Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of four hundred fourteen cases”
por: Poulas, Konstantinos, et al.
Publicado: (2022)

Reply to “Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients”: To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out
por: Llamas-Velasco, Mar, et al.
Publicado: (2020)

Response to: “Reply to ‘Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients’: To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out”
por: Marzano, Angelo Valerio, et al.
Publicado: (2020)

Comment on “Androgenetic alopecia present in the majority of patients hospitalized with COVID-19”
por: Bukovac, Domen, et al.
Publicado: (2021)

Reply to: “Comment on ‘Androgenetic alopecia present in the majority of patients hospitalized with COVID-19’”
por: Wambier, Carlos G.
Publicado: (2021)

Commentary
por: Shin, Daniel B., et al.
Publicado: (2021)

Reply to Letter to the Editor Regarding: “Applying to dermatology residency during the COVID-19 pandemic”
por: Kearns, Donovan G., et al.
Publicado: (2021)

Response to: “Applying to dermatology residency during the COVID-19 pandemic”
por: Alia, Erisa, et al.
Publicado: (2021)

COVID-19 compels closer scrutiny of disparities in dermatology
por: Temiz, Laurie A., et al.
Publicado: (2021)

Comment on “Cling film for mobile phones to prevent cross-infection during the COVID-19 pandemic”
por: Salman, Andac, et al.
Publicado: (2021)

Could antiphospholipid antibodies contribute to coagulopathy in COVID-19?
por: Parodi, Aurora, et al.
Publicado: (2020)

Virtual didactics exchanges to enhance trainee education
por: Shive, Melissa, et al.
Publicado: (2020)

Using cyclosporine in the COVID era: An emergent need for caution
por: Khurana, Ananta, et al.
Publicado: (2020)

Time to revisit the Health Insurance Portability and Accountability Act (HIPAA)? Accelerated telehealth adoption during the COVID-19 pandemic
por: Bhate, Chinmoy, et al.
Publicado: (2020)

Experience in patients with hidradenitis suppurativa and COVID-19 symptoms
por: Galán, José Luis, et al.
Publicado: (2020)

Conducting inpatient dermatology consultations and maintaining resident education in the COVID-19 telemedicine era
por: Hammond, Margaret I., et al.
Publicado: (2020)

Comment on: “To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out. Characterization of herpetic lesions in hospitalized COVID-19 patients”
por: Fernandez-Nieto, Diego, et al.
Publicado: (2020)

The new normal: An approach to optimizing and combining in-person and telemedicine visits to maximize patient care
por: Cohen, Jeffrey M., et al.
Publicado: (2020)

Optimizing education for dermatology residents during the COVID-19 pandemic
por: Patel, Parth, et al.
Publicado: (2020)

Prevalence of cheilitis in health care workers treating patients with COVID-19
por: Singh, Mehak, et al.
Publicado: (2020)

The digital divide: How COVID-19's telemedicine expansion could exacerbate disparities
por: Bakhtiar, Mina, et al.
Publicado: (2020)

Caution in the time of rashes and COVID-19
por: Vesely, Matthew D., et al.
Publicado: (2020)

Dermatology in the Black barbershop: A potential opportunity for expanding access and bridging gaps
por: Okoji, Uchenna K., et al.
Publicado: (2020)

Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
por: Kearns, Donovan G., et al.
Publicado: (2020)

A response to “Male balding is a major risk factor for severe COVID-19”
por: Thatiparthi, Akshitha, et al.
Publicado: (2021)

Reply to letter to the editor: “A response to ‘Male balding is a major risk factor for severe COVID-19’”
por: Yousaf, Ahmed, et al.
Publicado: (2021)

Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximab
por: Waldman, Reid A., et al.
Publicado: (2021)

If skin is a potential host of SARS-CoV-2, IL-17 antibody could reduce the risk of COVID-19
por: Xu, Qiannan, et al.
Publicado: (2021)

Androgenetic alopecia in COVID-19: Compared to what?
por: Nanes, Benjamin A.
Publicado: (2020)

In response to: “Reply to research letter”
por: Wan, Marilyn T., et al.
Publicado: (2020)

Reply to research letter
por: Rivera-Oyola, Ryan, et al.
Publicado: (2020)

Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign
por: Wambier, Carlos Gustavo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qnld1qv9k9eqkn92biftiur4o6